Theriva Biologics inc (TOVX) - News Archive

Theriva Biologics Inc. has recently captured the attention of both the medical and financial communities. With anticipated presentations at high-profile medical meetings, particularly highlighting the VCN-01 expanded da...

Theriva Biologics: Innovating in Oncological Therapeutics with Strategic Offering Advancements and Positive Clinical Trial ResultsROCKVILLE, Md. May 07, 2025 Theriva Biologics (NYSE American: TOVX) is a company firmly o...

Navigating New Frontiers: Theriva Biologics Advances Cancer Therapy Research with Promising Clinical Trials In the rapidly evolving landscape of oncology, clinical-stage companies are at the forefront of introducing inn...

Theriva Biologics Announces $2.5 Million Public Offering Amid Unprecedented Challenges in the Fight Against Metastatic Pancreatic CancerIn a strategic move indicative of both resilience and opportunity in the face of mo...

In a landscape where therapeutic advancements for metastatic pancreatic cancer remain critically needed, Theriva Biologics has made notable strides through its VIRAGE Phase 2b clinical trial. Targeting pancreatic ductal...

In a groundbreaking development, Theriva Biologics, a leading clinical-stage company focused on cancer therapeutics, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to...

Theriva Biologics, a clinical-stage company focusing on cancer therapeutics, has recently announced the acceptance of its phase 2b clinical trial, VIRAGE, for presentation at the 2024 American Society of Clinical Oncolo...

Biopharmaceutical company Theriva Biologics has recently announced encouraging topline data from an investigator-sponsored Phase 1 trial of intravitreal VCN-01, a therapeutic treatment used against refractory retinoblas...

In the realm of cancer research, Theriva Biologics, a prominent biotech company, aims to revolutionize pancreatic cancer treatment. Their lead product candidate, VCN-01, has shown promising preclinical results in combin...

Theriva Biologics Receives Positive Recommendation for VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma TrialTheriva Biologics, a leading biopharmaceutical company, announced today that the Independent Data Monitor...